NCT03158129 2026-04-06
Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
32 trialsNCT03377023 2026-04-02
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03425331 2026-01-08
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT02259621 2025-12-03
NA_00092076
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03573947 2025-10-14
TOP1705
Duke University
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04026412 2025-07-24
CheckMate73L
Bristol-Myers Squibb
Phase 3 Completed
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT03262779 2025-01-09
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Yale University
Phase 2 Completed
NCT03001882 2024-05-20
CheckMate 592
Bristol-Myers Squibb
Phase 2 Completed
NCT05005273 2024-02-28
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02864251 2023-09-28
CheckMate722
Bristol-Myers Squibb
Phase 3 Completed
NCT03302234 2023-09-26
KEYNOTE-598
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02658890 2023-08-28
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02659059 2023-04-05
CheckMate 568
Bristol-Myers Squibb
Phase 2 Completed
NCT03663166 2023-02-15
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT03347123 2022-02-28
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Incyte Corporation
Phase 1/2 Terminated
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01820754 2021-02-26
TOP1201 IPI
Duke University
Phase 2 Completed
NCT02221739 2020-05-11
Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NYU Langone Health
Phase 1/2 Completed
NCT02279732 2019-08-28
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
Bristol-Myers Squibb
Phase 3 Completed
NCT00527735 2018-07-18
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Bristol-Myers Squibb
Phase 2 Completed
NCT01165216 2014-07-22
Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT01471197 2014-05-12
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated